Dostarlimab + Chemo Beneficial for Advanced, Recurrent Endometrial Cancer
By Elana Gotkine HealthDay Reporter
MONDAY, June 9, 2025 -- For patients with advanced or recurrent endometrial cancer, dostarlimab plus carboplatin-paclitaxel treatment is associated with improved survival and maintenance of quality of life, according to a study published online May 21 in the International Journal of Gynecological Cancer.
Dana M. Chase, M.D., from the David Geffen School of Medicine at the University of California, Los Angeles, and colleagues randomly assigned patients with primary advanced or recurrent endometrial cancer to receive dostarlimab/placebo plus carboplatin-paclitaxel chemotherapy every three weeks for six cycles followed by dostarlimab/placebo monotherapy every six weeks for up to three years. Data were used from the first interim analysis (Sept. 28, 2022) and quality of life was assessed with the EuroQoL 5-Dimensions 5-Level questionnaire.
Overall, 241 and 246 patients in the dostarlimab and placebo arms, respectively, were analyzed for safety. The researchers found that the mean duration of quality-adjusted time without symptoms of disease progression or toxicity of treatment was significantly longer in the dostarlimab arm than the placebo arm in the overall population (24.75 versus 20.34 months). Regardless of mismatch repair/microsatellite instability status or toxicity criteria used, benefits in quality-adjusted time without symptoms of disease progression or toxicity of treatment were observed after dostarlimab treatment; benefits were mainly driven by time without symptoms of disease.
"This is the first study to demonstrate a statistically significant improvement in both overall survival and quality-adjusted survival with an immunotherapy-chemotherapy combination in this disease setting," Chase said in a statement. "It's a major step forward in the treatment of endometrial cancer."
Several authors disclosed ties to pharmaceutical companies, including GlaxoSmithKline, which manufactures dostarlimab and funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2025
Read this next
One in 10 Undergoing Early Cancer Surgery Have New Persistent Opioid Use
MONDAY, Sept. 8, 2025 -- More than one in 10 veterans undergoing surgery for early-stage cancer develop new persistent opioid use, according to a study published online Sept. 8 in...
Healthy Plant-Based Diet May Cut Burden of Multimorbidity of Cancer and Cardiometabolic Diseases
MONDAY, Sept. 8, 2025 -- Among middle-aged and older adults, a healthy plant-based diet may reduce the burden of cancer and cardiometabolic diseases, according to a study...
Moderate-to-Severe TBI Linked to Malignant Brain Tumor Risk
FRIDAY, Sept. 5, 2025 -- A history of moderate-to-severe traumatic brain injury (TBI) is associated with an increased risk for developing malignant brain tumors, according to a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.